Cancer Biomarkers Market Analysis

  • Report ID: 4552
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Cancer Biomarkers Market Analysis

Cancer Type (Breast, Lung, Prostate, Colorectal, Stomach, Other Cancers)

The global cancer biomarkers market is segmented and analyzed for demand and supply by cancer type into breast, lung, prostate, colorectal, stomach, and other Cancers. Out of these segments, the breast cancer segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the rising prevalence of breast cancer on account of unhealthy lifestyles, genetic inheritance, the rising female geriatric population, and exposure to hazardous radiation. As per the World Health Organization, in 2020, about 2.3 billion women are diagnosed with breast cancer, and 685,000 people died across the world.

Profiling Technology (Omics Technologies, Imaging Technologies, Immunoassays)

The global cancer biomarkers market is also segmented and analyzed for demand and supply by profiling technology into omics technologies, imaging technologies, and immunoassays. Amongst these three segments, the omics technologies segment is expected to garner a significant share. The growth of the segment can be attributed to the high efficiency of omics technologies in the diagnosis of cancer, along with the increasing development of profiling techniques for cancer biomarkers, that is anticipated to boost the market’s growth during the forecast period.

Our in-depth analysis of the global cancer biomarkers includes the following segments:

              By profiling Technology

  • Omics Technologies
  • Imaging Technologies
  • Immunoassays

              By Biomolecule

  • Genetic
  • Protein
  • Glyco Biomarkers

              By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Stomach Cancer
  • Others

              By Application

  • Diagnostics
  • Drug Discovery & Development Prognosis
  • Risk Assessment
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4552
  • Published Date: Oct 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of cancer biomarkers is evaluated at USD 18.65 billion.

The cancer biomarkers market size was over USD 16.8 billion in 2024 and is anticipated to exceed USD 90.3 billion by the end of 2037, growing at over 13.7% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of cancer, elevating R & D activities and investments, rising use of biomarkers in the medical sector will boost the market growth.

North America industry is expected to dominate largest revenue share by 2037, due to rising population count & growing research activities, followed by the surging ratio of health insurance covering various cancer biomarker diagnoses in the region.

The major players in the market include INOVIQ, Bio-Rad Laboratories, Inc., Abbott Laboratories, Becton, Dickinson and Company, Merck KGaA, CENTOGENE GmbH, PerkinElmer Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Bristol Myers Squibb Company (BMS).
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample